NASDAQ · Biotechnology

CMND (CMND) Stock

$1.62 +0.52% NASDAQ: CMND Healthcare

Valuation

MetricValue
Price$1.62
Market Cap$2.41M
P/E Ratio-0.79
P/B Ratio0.03
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$524.00
52-Week Low$1.59
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-400.00%
ROA-66.67%
ROCE-600.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity2.00
Current Ratio1.20

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-4.0M$-9.0M$-9.0M$-8.0M$-6.0M
Net Profit$-4.0M$-10.0M$-12.0M$-7.0M$-4.0M
EPS$-473.10$-916.44$-234.13$-9.44$-3.03
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$4.0M$1.0M$6.0M$10.0M$6.0M
Total Liabilities$0$3.0M$5.0M$6.0M$5.0M
Cash$4.0M$0$5.0M$9.0M$4.0M
Borrowings$0$0$0$0$2.0M

Latest News

Clearmind Medicine Expands Global IP Portfolio With Hong Kong Patent Filing MT Newswires · Jul 20, 2026 Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market GlobeNewswire · Jul 20, 2026 Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction GlobeNewswire · Jul 17, 2026 Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI GlobeNewswire · Jul 16, 2026 Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial GlobeNewswire · Jul 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-5.0M$-6.0M$-7.0M$-5.0M
Investing Cash Flow$0$0$0$0$-1.0M
Financing Cash Flow$0$0$1.0M$6.0M$0
Net Cash Flow$3.0M$-4.0M$5.0M$2.0M$-3.0M
Free Cash Flow$-2.0M$-5.0M$-6.0M$-7.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-241.30%
Quick Ratio3.79
Interest Coverage—
Return 1Y-99.53%
Return 3Y-99.97%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
CLDI $0.11 +0.18% -0.03 $802266 0.00%
CNSP $5.40 +0.75% -0.14 $3.10M 0.00%
GRI $1.46 -5.81% -0.33 $131155 0.00%
JAGXJaguar Health, Inc. $0.93 -3.48% 0.00 $61962 0.00%

About CMND

CMND is led by CEO Adi Zuloff-Shani, employs 4 people, headquartered in CA, publicly traded since 2022.

CMND stock trades at $1.62 with a market capitalization of $2.41M. The stock is valued at a price-to-earnings (P/E) ratio of -0.79, price-to-book of 0.03, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.59 and $524.00, and currently trades 99.7% below its 52-week high.

On profitability, CMND generates a return on equity (ROE) of -400.00%, return on capital employed of -600.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides